This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. First PDE4 inhibitor for psoriasis hits the market but impact is uncertain. Nat Biotechnol 32, 505–506 (2014). https://doi.org/10.1038/nbt0614-505
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0614-505
This article is cited by
-
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances
Drugs (2020)
-
IL-17–targeting biologics aim to become standard of care in psoriasis
Nature Biotechnology (2015)
-
Celgene shells out for antisense drug
Nature Biotechnology (2014)